Albright Carol, Garst Jennifer
Department of Medicine, Duke University Medical Center, Durham, NC 27710, USA.
Curr Oncol Rep. 2007 Jul;9(4):241-6. doi: 10.1007/s11912-007-0029-9.
Lung cancer is the leading cause of death from cancer worldwide. First-line therapy is based on stage at diagnosis and can include chemotherapy, radiation, and surgery. Despite advances, the prognosis for advanced-stage lung cancer is very poor. Vaccines with the capability to activate the host immune system may have a role in second-line therapy. Advances in the understanding of cellular and molecular immunology are forming the basis for improving vaccine therapy. Most trials to date have demonstrated safety but inconsistent efficacy. Further research is needed to enhance this potential.
肺癌是全球癌症死亡的主要原因。一线治疗基于诊断时的分期，可包括化疗、放疗和手术。尽管取得了进展，但晚期肺癌的预后仍然很差。具有激活宿主免疫系统能力的疫苗可能在二线治疗中发挥作用。对细胞和分子免疫学认识的进展正在为改进疫苗治疗奠定基础。迄今为止，大多数试验已证明其安全性，但疗效并不一致。需要进一步研究以增强这种潜力。
